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Abstract
High Throughput Biological Data (HTBD) requires detailed analysis methods and from a life science perspective, these
analysis results make most sense when interpreted within the context of biological pathways. Bayesian Networks (BNs)
capture both linear and nonlinear interactions and handle stochastic events in a probabilistic framework accounting for
noise making them viable candidates for HTBD analysis. We have recently proposed an approach, called Bayesian Pathway
Analysis (BPA), for analyzing HTBD using BNs in which known biological pathways are modeled as BNs and pathways that
best explain the given HTBD are found. BPA uses the fold change information to obtain an input matrix to score each
pathway modeled as a BN. Scoring is achieved using the Bayesian-Dirichlet Equivalent method and significance is assessed
by randomization via bootstrapping of the columns of the input matrix. In this study, we improve on the BPA system by
optimizing the steps involved in ‘‘Data Preprocessing and Discretization’’, ‘‘Scoring’’, ‘‘Significance Assessment’’, and
‘‘Software and Web Application’’. We tested the improved system on synthetic data sets and achieved over 98% accuracy in
identifying the active pathways. The overall approach was applied on real cancer microarray data sets in order to investigate
the pathways that are commonly active in different cancer types. We compared our findings on the real data sets with a
relevant approach called the Signaling Pathway Impact Analysis (SPIA).
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input list and the target pathway. All aferomentioned methods use
some variation of the main idea that a functional class is relevant
to the observed HTBD if the class possesses a statistically
significant amount of the input gene list.
We have recently proposed an approach, called Bayesian
Pathway Analysis (BPA), for analyzing HTBD using BNs [8]. In
the BPA framework known pathways are modeled as BNs and the
processed HTBD is used to score each network to assess its fitness
to the observed data; achieving a workflow that incorporates in its
model the topology of the pathways. There have since been
approaches that model the pathway topology to some degree in
the analysis of HTBD [9–14]. In terms of general applicability and
direct relation to the output of BPA, we have used the Signaling
Pathway Impact Analysis (SPIA) [15] in our comparisons. SPIA
combines the GSA based pathway activation measure with a novel
pathway perturbation score, which reflects the degree to which the
deregulation of the genes in the pathway is in concordance with
the signaling hierarchy.
In the BPA approach, pathways are retrieved from the KEGG
database [16]. Each entry (node) in the pathway is mapped to an
internal unique ID and a conversion module carries out the
necessary mapping between the input gene expression IDs and the
pathway node IDs. Repeating entries in the pathway are merged
and represented as a single node while conserving edge relations.
BN theory utilizes Directed Acyclic Graphs (DAG) but there may
exist cycles in the biological pathways. This is overcome using
Spirtes’ method where graph representations of structural
equation models [17] are converted to collapsed acyclic graphs

Introduction
Bayesian Network (BN) models have gained popularity for
learning biological pathways from microarray gene expression
data [1,2]. BNs represent dependency structure for a set of
random variables using directed acyclic graphs and have been
used with increasing popularity in mathematics and computational
sciences over the past 20 years. However, current BN applications
are limited to structure learning using observed data and therefore
work only on a few hundreds of variables as structure learning
algorithms are computationally complex. This, in turn, results in
inefficient use of HTBD, which contain a much larger number of
variables.
From a life sciences perspective, data analysis results make most
sense when interpreted within the context of biological networks
and pathways. Previously established individual gene analysis
based methods have been extended to network and pathway scale
mostly along the lines of gene set analysis (GSA) [3,4] or Gene
Ontology (GO) based approaches [5–7], which focuses on
determining predefined gene sets or classes that are significantly
regulated. However, these approaches consider the input genes
and the target gene sets and classes simply as lists and do not
incorporate in their models the topology via which genes in these
classes interact with each other. Other popular commercial
approaches, such as the Ingenuity Pathway Knowledge Base
(Ingenuity Inc., California) or PathwayAssist (Ariadne Genomics,
California) also identify known pathways as active based on
HTBD simply by considering the number of genes shared by the
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such that d-separations in the collapsed graph entail the same
independency relations defined by the model. To this end, a
biological pathway is modeled as a BN, which now can be tested
against input data to assess its fitness.
BPA assumes a two-group (e.g. case vs. control) normalized
gene expression data as input. The observation matrix to score
each DAG is obtained by generating the fold change (FC) values
for each pair of samples in the two groups. In this matrix, columns
represent genes in the DAG and rows represent pairwise
comparisons. If there are N1 and N2 samples in the two groups,
the observation matrix consists of N16N2 rows. Each column
represents the FC for the corresponding gene in each of the
N16N2 pairwise comparisons. These continuous FC values are
discretized using a cut-off of 2. If the FC value is greater than 2 or
less than 0.5 (i.e. the gene is deregulated), it is converted into 1,
and otherwise it is converted into 2.
The degree to which a pathway explains given HTBD is
measured using the Bayesian Dirichlet equivalent (BDe) score with
equivalent sample size method [18]. In this phase, the BN is
updated with the observation matrix during the score calculation.
Statistical significance of this measurement is assessed by testing it
against datasets generated by applying randomization via bootstrapping where the observed score is ranked against scores
obtained from randomized data sets. Bootstrapping is applied to
the columns of the observation matrix providing a randomization
of the rows, which are used in scoring. The results are evaluated in
terms of nominal p-values and false discovery rate (FDR) values
correcting for multiple hypotheses testing.
In this paper, we have two fundamental aims. Our first aim is to
improve on the BPA system by using the following strategies. In
order to optimize the discretization phase, we tried Equal Width,
Equal Frequency, K-means, Column K-means, Bi-directional Kmeans, and Automatic Threshold Discretization [19,20] in
addition to the hard-cut-off levels offered by BPA. In the scoring
phase, we applied Akaike Information Criterion (AIC) [21],
Bayesian Information Criterion (BIC) [22], and Factorized
Normalized Maximum Likelihood (fNML) [23] and compared
the results with the BDe scoring scheme. The significance
assessment phase was changed so that random data sets were
obtained at the gene signal level. In this approach, samples in each
of the two classes are randomly permuted to provide new data sets
[24]. Each new data set (with new class assignments for each
sample) is run through the complete workflow and a score value is
calculated. This way, we overcome the cases where the current
BPA approach fails to provide randomized data sets. In testing
these new approaches, we generated synthetic microarray data
that simulates gene expression from N pathways where a subset,
Na, of these pathways is active. A performance criterion is assessed
by the accuracy of predicting active and passive pathways. In
addition to improving the memory and CPU usage of the
algorithm, we also added new organisms for which the BPA system
can be used and we provide a web portal at http://bioinfo.unl.
edu/bpa/ which hosts the stand-alone version of the optimized
software along with a tutorial and example data sets.
Our second aim in this study is to apply the improved pathway
analysis approach on real cancer data sets. For this purpose, we
downloaded real microarray data sets from the NCBI’s GEO
database regarding bladder, brain, breast, colon, liver, lung,
ovarian and thyroid cancers. We investigated the pathways that
are commonly identified as active in these various cancer
microarray data sets.

PLOS ONE | www.plosone.org

Methods
Class Label Permutation
In the original BPA system, the observation data matrix for BN
scoring is composed of the 2-level discretized FC levels for the
genes in the network to be scored. The degree to which a pathway
explains given HTBD is measured using the ‘‘Bayesian Dirichlet
equivalent’’ (BDe) score and the statistical significance of this
measurement is assessed by randomization via bootstrapping
where the observed score is ranked against scores obtained from
randomized data sets. Randomized data sets are obtained by
changing the structure of the columns of the observation matrix
via sampling with replacement of each column separately.
In Table 1, we show two sample instances of such input
matrices. Here, columns denote the genes and rows denote the
pairwise comparison of the samples in the two sample groups (e.g.
cancer vs. normal). The aferomentioned randomization method
(originally employed by BPA) works successfully when an
observation matrix as in Table 1 (a) is the case where a given
column does not consist only of one type of observation. However,
if the observation matrix turns out to be as in Table 1 (b), where
columns represent only one type of observation, randomizing the
columns of the observation matrix will not result in any change.
Therefore, the scores obtained by randomized data sets will be the
same, making the significance assessment almost impossible to
achieve. It is possible to obtain matrices as in the latter case, i.e. a
matrix where a given column consists only of the same level, when
a gene shows the same degree and direction of change between the
two classes. In other words, if a gene in a given pathway is
consistently 2 or more FC upregulated in one class versus the
other, we would end up having the column for this gene to consist
only of the same discretization level.
In order to overcome this problem, we applied the permutation
method previously described to randomize gene expression data
sets [24]. This randomization is done by replacing the samples of
each class randomly. Suppose we have a dataset composed of 10
normal and 10 cancer samples. In one instance of the permutation, for example, 3rd, 5th, and 6th normal samples are replaced
with 1st, 7th, and 9th cancer samples. The observation matrix is
generated by pairwise comparison of the signal values over the
new order of two classes followed by discretization. This procedure
is repeated B times and pathway scores are calculated using the
discretized matrices. As a result, the statistical significance of the
observed score can be assessed accurately via ranking against
scores obtained from different observation matrices generated by
these B randomized data sets. If the score of a given pathway is Sn,
its p-value is assessed using

PðSn Þ~

B
1X
I ðSk wSn Þ
B k~1

where I(a) is 1 if a is ‘‘true’’ and 0 otherwise. The significance of
each pathway is reported as this nominal p-value and the
corresponding false discovery rate (FDR) calculated using the
Benjamini-Hochberg procedure [25]

Discretization
BPA utilized a discretization method such that the continous FC
value is represented as 1 if it’s greater than 2 or less than K (i.e. a
gene is dysregulated), and as 2 otherwise. Another use of the 2level discretization is choosing a cut-off value of 3, i.e., the FC is
represented as 1 if its value is greater than 3 or less than 1/3 and as
2 otherwise. In 3-level discretization with the cutoff value 2, the
2
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fold change is represented as 1 if its value is greater than 2, as 2 if
less than K, and as 3 otherwise. In 3-level discretization with the
cut-off value of 3, the fold change is represented as 1 if its value is
greater than 3, as 2 if less than 1/3, and as 3 otherwise.
In this study, we propose new discretization methods [19,20] to
be utilized in processing the observed fold change values for use by
Bayesian scoring metrics. An N-by-M matrix E is used to denote
the observed FC matrix, where N is the number of pairwise
comparisons and M is the number of genes. E(n,m) denotes the
FC value of comparison n for the gene m. E(n,:) denotes FC data
of comparison n for all genes, and E(:,m) denotes the FC data of
gene m for all the comparisons.
Equal Width Discretization (EWD). EWD divides the
observation matrix row n into k intervals of equal width between
E(n,:)min and E(n,:)max. Thus the intervals of comparison n have
width w = (E(n,:)max - E(n,:)min)/k, with boundary points at
E(n,:)min +w, E(n,:)min +2w, …, E(n,:)min + (k - 1)w where k is a
positive integer.
Equal Frequency Discretization (EFD). EFD divides the
sorted E(n,:) into k intervals so that each interval contains the
same number of FC values.
K-means Discretization. K-means divides E(n,:) into k
intervals by k-means clustering so that similar FC values of
comparison n are placed in the same interval.
Column K-means Discretization (Co-k-means). Co-kmeans divides E(:,m) into k intervals by k-means clustering so
that similar FC values for the gene m are placed in the same
interval.
Bidirectional K-means Discretization (Bi-k-means). In
the bi-k-means method both k-means and co-k-means are
respectively implemented with parameter k+1, giving every FC
value two discretized values. If the product of the two values is
equal to or greater than x2, and less than (x+1)2, the final
discretized value of this expression value is x, where x is a positive
integer ranging from 1 to k.
Automatic Threshold Discretization. There are two options for the automatic threshold discretization, which iteratively
determines the cut-off values by minimizing the variance. The
whole FC data E is divided into two intervals according to a
certain cut-off value in the global option. The local option of this
method divides E(:,m) into two intervals according to the cutoff
values defined for each column (gene) separately.
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In addition to the BDe scoring scheme, we propose the
following score metrics to be used in the BPA system.
Akaike Information Criterion (AIC). AIC is one of the
most commonly used information criteria, which selects the model
that minimizes the negative likelihood penalized by the number of
parameters [21]:

Columns denote genes/nodes; rows denote observations.
doi:10.1371/journal.pone.0102803.t001
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Table 1. Sample Observation Matrices.

Scoring

^ ðDDM Þ{p
AIC ðM,DÞ~ log P
^ ðDDM Þ is the maximum likelihood of the model M, D is
whereP
observed data, and p is the number of parameters in the model.
Bayesian Information Criterion (BIC). BIC is another
widely used information criteria and unlike AIC, BIC is consistent
and improves in performance with large sample sizes [22]. BIC is
defined as:
^ ðDDM Þ{ p ðlog N Þ
BIC ðM,DÞ~ log P
2

3
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The datasets, which are used for the performance measurement
of discretization methods, are also used for the assessment of the
scoring methods. The obtained prediction accuracies are listed in
Table 2. According to the simulation results, the best scoring
method is the fNML method, which estimates whether a pathway
is active or not with an accuracy of 0.98460,016. Therefore, the
2-level k-means discretization and fNML scoring methods are used
for the real microarray data analysis as this combination achieved
the highest accuracy.
In Table 3, we list the 12 real cancer microarray data sets (GEO
Numbers, cancer types, and numbers of samples) and the number
of pathways identified as active by BPA and SPIA analyses. In
Tables S2 and S3, we list the complete list of pathways deemed
active by the BPA and SPIA methods for each real cancer
microarray dataset, respectively. In total, BPA identified 171
pathways that have been found significant in at least one of the
data sets. 15 of these pathways have been found to be significant in
at least half of the data sets and therefore potentially represent
mechanisms common to different cancer types (see Table S2).
We also investigated the commonality of significant pathways in
cancer types represented by two data sets except for the thyroid
cancer, which has resulted in very few significant pathways. These
results for the BPA analysis are summarized in Figure 1. In the
case of brain and liver cancer data sets, the common pathways
consist of 52% and 59% of the dataset with the smaller number of
pathways. In the breast cancer data sets, we see a lesser degree of
agreement (,31%). These commonalities are 60%, 41%, and
52% for the brain, breast, and liver datasets, respectively, using the
SPIA analysis. However, SPIA uses a subset of the pathways
investigated by the BPA system. When we consider only the
pathways in the SPIA database, the commonalities in the BPA
analysis are 73%, 45%, and 71% for the brain, breast, and liver
datasets, respectively.
In Figure 2, we list the number of pathways identified by the
two analysis methods when the pathway database is restricted to
the one used by SPIA. On average, the number of pathways found
to be significantly active by both methods is about 60% of the
pathways of the algorithm with the smaller number of active
pathways.
Although the improved BPA system outperformed the old BPA
system on synthetic data sets (data not shown), we compared the
performance of both methods on the real cancer microarray data.
The list of pathways deemed significant by the old BPA system is
represented in Table S4. The old BPA analysis revealed 127
pathways active in at least one of the cancer data sets and 18 of the
pathways were found to be common to at least half of the data sets.
In Table S5, we list the numbers of pathways identified as active
by both BPA systems and indicate the number of pathways
commonly identified by the two methods in each cancer data set.
These results on the real cancer data sets (Tables S4 and S5)
indicate that the old BPA system fails to exhibit consistency for
some of the datasets (e.g. 57 vs. 1 pathway identified by the new vs.
old PBA in the ‘‘bladder’’ data set; 16 vs. 3 pathways identified by
the new vs. old PBA in the ‘‘breast’’ data set; 58 vs. 0 pathway
identified by the new vs. old PBA in the ‘‘lung’’ data set; and 10 vs.
0 pathway identified by the new vs. old PBA in the ‘‘thyroid’’ data
set). We believe this is mainly due to the permutation test method
introduced in the new BPA system where the old system fails to
generate randomized data sets in pathways showing a constant
fold change direction for its members (see Table 1). Some of the
performance improvement can be attributed to the optimized
discretization and scoring methods incorporated in the new BPA
system. The old and new BPA sytems show, on average, a 28%
overlap between the pathways identified in each data set. This

BIC differs from AIC only in the second term, which depends
on the sample size N.
Factorized
Normalized
Maximum
Likelihood
(fNML). Silander et al. [23] developed the fNML score based

on the normalized maximum likelihood (NML) distribution
[26,27]. Given a data set D, the NML model selection criterion
chooses the model M for which PNML ðDDM Þ is largest.
^ ðDDM Þ
P
PNML ðDDM Þ~ X
^ ðD’DM Þ
P
D’
where the normalization is done over all data sets D9 of the same
size as D. After taking the logarithm, the score is in a form of
penalized log-likelihood given G = {G1,…,Gm} as the parent set in
the DAG (i.e. Gi is the parent set of the node Xi in the DAG):




SfNML Di ,DGi ~ log PNML Di DDGi
X




^ Di DDG { log
^ D’i DDG
~ log P
P
i
i
D’
i

where the normalizing sum goes over all the possible Di column
vectors. Even though the penalty term has an exponential number
of terms, it can be evaluated efficiently using a linear-time
algorithm introduced in [28]. By calculating the penalty term for
each variable in the dataset, the NML becomes factorized.

Data Sets
We generated synthetic transcriptional regulatory networks and
produced simulated gene expression data with noise using
SynTReN v1.12 [29]. We created 55 synthetic networks that
mimic biological pathways with sizes ranging from 7 to 200. We
randomly selected 20 out of 55 pathways to be active and
SynTReN generated the corresponding expression datasets for 20
test and 20 control samples with 2249 genes adding a 4% noise
level.
To test the optimized and improved BPA performance on real
data sets, we used 1 bladder, 2 brain, 2 breast, 1 colon, 2 liver, 1
lung, 1 ovarian, and 2 thyroid cancer data sets. In choosing the
data sets, we fixed the platform to be Affymetrix to prevent bias
and used data sets where tumor and normal samples are clearly
defined and the cancer samples are as homogenous as possible.
Most of the chip data came from the Affymetrix HG-U133 Plus
2.0 GeneChip, which is composed of more than 54,000 probe sets
representing over 47,000 transcripts providing a comprehensive
picture of the human transcriptome. Other chip types include HGU133A and HG-U133A_2, which represent approximately 22,000
probesets. Prior to application of the proposed approach, raw
microarray data has been normalized using Affymetrix Microarray
Analysis Suite (MAS) 5.0 algorithm [30].
For each data set, we applied the proposed analysis method with
1000 permutations and assessed significant pathways with a
nominal p-value of 0.05 and an FDR of 0.25.

Results
In Table S1, we list the accuracy levels (if a network is correctly
called active/inactive) of the different discretization schemes for 10
simulated datasets (D1–D10). According to the simulation results,
the best discretization method is the 2-level k-means discretization
applied to the rows of the observation matrix. This approach
achieves an accuracy of 0.96260,031. Therefore, 2-level k-means
method is used as the discretization method for the experiments to
determine the best scoring criterion.
PLOS ONE | www.plosone.org
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Table 2. Prediction accuracy of different scoring methods on synthetic datasets.

BDe

AIC

BIC

fNML

D1

0.945

0.964

0.909

1.000

D2

0.982

1.000

0.927

0.964

D3

0.982

1.000

0.945

1.000

D4

0.964

0.982

0.982

1.000

D5

0.945

1.000

0.891

1.000

D6

0.945

0.982

0.982

0.964

D7

0.982

0.982

0.927

0.982

D8

1.000

0.982

0.964

0.982

D9

0.982

0.982

0.927

0.982

D10

0.891

0.945

0.945

0.964

Avg

0.962

0.982

0.940

0.984

SD

0.031

0.017

0.030

0.016

BDe: Bayesian Dirichlet Equivalent; AIC: Akaike Information Criterion; BIC: Bayesian Information Criterion; fNML: factorized Normalized Maximum Likelihood.
doi:10.1371/journal.pone.0102803.t002

level of agreement is significantly lower than the one observed
between the new BPA and SPIA methods, which showed 60%
overlap on average. Moreover, we obtained a 25% overlap on
average between the old BPA and SPIA methods when the
pathways identified for each real cancer microarray data set by the
two methods were considered.
We also applied the improved BPA method on the NCI-60
cancer cell line microarray data set used in describing the Gene
Set Enrichment Analysis (GSEA) method [31]. This data set
contains microarray results (run on the Affymetrix HGU95Av2
platform) for 50 of the NCI-60 cell lines (www.broadinstitute.org/
gsea/datasets.jsp). We used this data set to identify pathways
deregulated following a mutation in the tumor suppressor p53
gene. Out of the 50 samples, 17 are wild type and 33 carry
mutations in the p53 gene. The pathways identified as active by
BPA due to the mutations in p53 are listed in Table 4.

Discussion
Our synthetic data simulations identified k-means clustering as
the best performing discretization method. We find this result
reasonable as k-means uses the distribution in the data to minimize
the total mean squared error with respect to the discretized values
and the real FC occurrences. Also based on the synthetic data
results, the scoring method that yielded the highest accuracy was
the factorized normalized maximum likelihood (fNML) score [23].
This result was also expected as it has been shown that the BDe
scoring scheme is very sensitive to the choice of prior hyperparameters and AIC and BIC require some manual parameter
setting and do not work well with small data sets, which is
occasionally the case with HTBD [32]. fNML on the other hand is
an information theory based optimized scoring method that has no
tunable parameters.
In the real microarray data analysis using BPA, the pathway
that came out in most of the cancer data sets as significantly active

Table 3. Cancer Data Sets and numbers of active pathways Identified by BPA and SPIA analyses.

GEO# (GSE)

Cancer Type

Chip Type (HG-U133)

# of Samples

BPA

SPIA

7476

bladder

Plus2

12 (9C, 3N)

57

40

12907

brain

A

25 (21C, 4N)

81

23

15824

brain

Plus2

35 (30C, 5N)

46

32

8977

breast

Plus2

22 (7C, 15N)

16

25

22544

breast

Plus2

18 (14C, 4N)

66

36

41328

colon

Plus2

20 (10C, 10N)

36

39

14520

liver

A2

43 (22C, 21N)

77

22

14323

liver

A2

66 (47C, 19N)

59

17

10799

lung

Plus2

19 (16C, 3N)

58

43

14407

ovarian

Plus2

24 (12C, 12N)

5

18

3678

thyroid

Plus2

14 (7C, 7N)

4

27

6004

thyroid

Plus2

18 (14C, 4N)

10

27

doi:10.1371/journal.pone.0102803.t003
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Figure 1. Commonality of significant pathways using the BPA analysis on the same cancer types.
doi:10.1371/journal.pone.0102803.g001

(8/12) is the Cell adhesion molecules (CAMs) pathway. CAMs are
located on the cell surface and participate in the activity of a cell
binding with other cells. One of the primary features of cancer
cells is uncontrolled growth where the cells are immune to densitydependent inhibition. Cancer cells keep on growing, forming
multiple levels, even when the cell density is increased. This is
mainly due to the malfunctioning in CAMs, which has been shown
to play an important role in cancer progression [33] and
disrupting important signal-transduction pathways [34]. Specifically, CAMs have been shown to be involved in brain [35],
bladder [36], breast [37], liver [38], lung [39] and thyroid [40]
cancer; the cancer data sets where the proposed system found the
CAM pathway as significantly activated.
Other pathways that need to be emphasized are ‘‘Citrate
(TCA/tricarboxylic acid) cycle’’, ‘‘Complement and coagulation
cascade’’ and ‘‘Adipocytokine signaling’’ pathways that are found
to be significantly active in 7 cancer data sets out of 12. Citrate
cycle, also known as the tricarboxylic acid cycle (TCA cycle) or the
Krebs cycle, is part of cellular respiration. It is a series of chemical
reactions used by all aerobic organisms to generate energy. Its
central importance to many biochemical pathways suggests that it
was one of the earliest parts of cellular metabolism to evolve [41].
A recent study identified this cycle as a cancer-specific metabolic
pathway [42]. In a wide range of tumor cells including the types
included in our datasets, it is found that a mutation causes this
cycle to run in reverse. Complement and coagulation cascade
pathway can be explained in two parts: the complement system is
a proteolytic cascade in blood plasma and a mediator of innate

immunity, a nonspecific defense mechanism against pathogens,
and blood coagulation is another series of proenzyme-to-serine
protease conversions. This pathway is identified as significant for
breast and liver cancer types in a functional cancer map, which
has been established following the analysis of functional expression
profiles of significantly enriched KEGG pathways across different
tumor entities assigned to various tumor classes [43]. Adipocytokine signaling pathway is positively correlated with leptin
production, which is an important regulator of energy intake
and metabolic rate. Leptin and adiponectin are the most abundant
adipocytokines and the best-studied molecules in this class so far.
Recent tumor biological findings on the role of the most
prominent adipocytokines leptin and adiponectin, which are
involved in tumor growth, invasion and metastasis, show the
effects of adipocytokines to brain and breast cancers [44], the types
of cancer datasets where the BPA system found this pathway as
significantly activated. There have been other additional studies
that have shown the relation of adipocytokine signaling pathway to
lung and liver cancers [59,60].
Our synthetic data results show that the improved BPA system
identifies the activity of a pathway with over 98% accuracy.
Although there is no gold standart in assessing the active pathways
regarding the real microarray data of a certain phenotype, BPA’s
reproducibility in the same cancer types has been over 50% in
average. When the pathway database is limited to the one used by
SPIA, this reproducibility exceeds 70%. Finally, when all the
cancer datasets are considered, the agreement between the two
methods is around 60%. Given the technical and biological

Figure 2. Number of pathways found significant in real microarray data sets using BPA and SPIA methods.
doi:10.1371/journal.pone.0102803.g002
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same cancer data sets in the old BPA system. For example, the old
system identified only 3 pathways in one of the ‘‘brain’’ data sets
compared to 122 pathways identified for another data set for the
same cancer type. These differences are very likely due to the
improved randomization, discretization, and scoring strategies
introduced in the current BPA system.
Pathways that have been identified as significantly activated by
BPA due to a p53 mutation are listed in Table 4. p53 is known to
be involved in ‘‘melanogenesis’’ (hsa04916) through skin hyperpigmentation due to its role in cytokine receptor signaling [51],
where alterations in p53 levels significantly affect the expression
levels of melanogenic factors. p53 plays a central role in
‘‘melanoma’’ (hsa05218) as a therapeutic agent [52] and risk
factor where certain signature hot-spot mutations in the p53 gene
result in oncogenic transformation. Among the pathways listed in
Table 4, p53 has been shown to be involved in ‘‘glioma’’
(hsa05214) [53] and ‘‘pancreatic cancer’’ (hsa5212) [54,55].
Recently, it has been shown that antigen specific (CD4+) T cell
response is critically affected by deregulation of p53 through ‘‘T
cell receptor signaling pathway’’ (hsa04660) [56]. p53 is also
known to be involved in ‘‘purine metabolism’’ (hsa00230) [57],
‘‘pyrimidine metabolism’’ (hsa00240) [58], and ‘‘fatty acid
biosynthesis’’ (hsa00061) [59,60]; other pathways identified as
active by BPA due to mutations in p53. Overall, BPA was clearly
able to identify pathways related to p53 using related microarray
data. We believe that utilized synthetic, real, and benchmark data
along with synthetic data sets render results that show the utility of
the improved BPA system as a new resource for pathway analysis
of HTBD.

Table 4. Significant pathways identified by the improved BPA
system using the NCI-60 microarray data set on samples with
and without p53 mutation (p53+: 17 Samples, p532: 33
samples).

ID

Name

hsa00650

Butanoate metabolism

hsa00061

Fatty acid biosynthesis

hsa05214

Glioma

hsa04916

Melanogenesis

hsa05218

Melanoma

hsa05212

Pancreatic cancer

hsa00230

Purine metabolism

hsa00240

Pyrimidine metabolism

hsa04660

T cell receptor signaling pathway

doi:10.1371/journal.pone.0102803.t004

variation, such a high degree of overlap between different pathway
analysis schemes is very promising.
In an attempt to identify patways specific to particular cancer
types, we investigated pathways that are consistently found to be
active for the same cancer types (and non-active for the other
cancer types) by the current BPA system. For brain cancer,
‘‘Parkinson’s disease pathway (hsa05012)’’ was found active in
both brain cancer data sets and only in one of the remaining 10
cancer data sets. Parkinson’s disease (PD) is one of the most
common neurodegeneretive disorders associated with cell loss in
the substantia nigra region of the midbrain [45]. Recently, there
have been studies that link the molecular mechanisms and genetic
dispositions of the disease to cancer. Mutations in PARK2, one of
the most common causes of early-onset PD, has been shown to
play a central role in glioblastomas [46] exhibiting changes in
almost identical residues in both the PD and the brain cancer
samples. Identification of this pathway as active almost uniquely
and consistently in brain cancer data sets implies that BPA is able
to identify biologically meaningful pathways based on the
underlying HTBD. In the liver cancer data sets, ‘‘Biotin
metabolism (hsa00641)’’ and ‘‘3-Chloroacrylic acid degradation
(hsa00780)’’ pathways were found to be active only in the two liver
data sets. Biotin concentration is known to be high in cancerous
tumors compared to normal tissues and biotin and other watersoluable vitamin B metabolisms have been shown to be important
in hepatocellular carcinoma [47,48]. Similarly, 3-Chloroacrylic
acid degradation pathway has been shown to be active in
hepatocellular carcinoma [49,50].
Comparison of the old BPA system with the improved one
proposed in this paper on the real cancer microarray data sets
revealed that the old BPA system fails to identify pathways for
some data sets and provides less biologically meaningful pathways
showing insignificant agreement with the improved BPA and SPIA
methods. Moreover, we see a less degree of agreement for the
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